New hope for cancer patients: drug may prevent wasting during treatment
NCT ID NCT07391826
First seen Feb 06, 2026 · Last updated May 22, 2026 · Updated 14 times
Summary
This study tests whether adding megestrol acetate oral suspension to standard chemoimmunotherapy can prevent weight loss and improve appetite in 48 people with stage III stomach cancer who are experiencing cachexia (severe wasting). Participants will either receive the drug plus standard treatment or standard treatment alone before surgery. The goal is to see if the drug helps patients maintain weight and feel better during treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Nanjing Medical Unviersity
Nanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.